You are here: Home » News-IANS » Health-Medicine
Business Standard

Cheap drug for common cold can stop spread of cancer

IANS  |  Tokyo 

A non-steroid, anti-inflammatory drug used for treating common cold has the potential to suppress the spread of bladder cancers as well as reduce their resistance to anti-drugs in mice, Japanese researchers have found.

Bladder -- the seventh most common in males worldwide -- can be grouped into two types: non-muscle-invasive cancer, which have a five-year survival rate of 90 per cent, and muscle-invasive cancer, which have poor prognoses.

The latter are normally treated with such anti-drugs as cisplatin, but tend to become chemo-resistant and, thus, spread to organs such as the lungs and liver, as well as bone, the study said.

The study conducted using animal model showed that injecting flufenamic acid -- a much cheaper cold drug -- into cancerous bladder cells can suppress the cells' invasive activities and restore the effectiveness of anti-drugs.

"The study could pave the way for medical institutions to use flufenamic acid which has unexpectedly been proven to be effective at fighting cancers," said Shinya Tanaka from Hokkaido University in Japan.

In the study, using rats the team created a xenograft bladder model, and discovered a three to 25-fold increase of the metabolic enzyme aldo-keto reductase 1C1 (AKR1C1).

It was also identified for the first time that AKR1C1 enhances tumour-promoting activities and proved the enzyme blocks the effectiveness of cisplatin and other anti-drugs, which can be inhibited by flufenamic acid, the researchers concluded in the paper published in the journal Scientific Reports.

--IANS

rt/py/vt

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Cheap drug for common cold can stop spread of cancer

A non-steroid, anti-inflammatory drug used for treating common cold has the potential to suppress the spread of bladder cancers as well as reduce their resistance to anti-cancer drugs in mice, Japanese researchers have found.

A non-steroid, anti-inflammatory drug used for treating common cold has the potential to suppress the spread of bladder cancers as well as reduce their resistance to anti-drugs in mice, Japanese researchers have found.

Bladder -- the seventh most common in males worldwide -- can be grouped into two types: non-muscle-invasive cancer, which have a five-year survival rate of 90 per cent, and muscle-invasive cancer, which have poor prognoses.

The latter are normally treated with such anti-drugs as cisplatin, but tend to become chemo-resistant and, thus, spread to organs such as the lungs and liver, as well as bone, the study said.

The study conducted using animal model showed that injecting flufenamic acid -- a much cheaper cold drug -- into cancerous bladder cells can suppress the cells' invasive activities and restore the effectiveness of anti-drugs.

"The study could pave the way for medical institutions to use flufenamic acid which has unexpectedly been proven to be effective at fighting cancers," said Shinya Tanaka from Hokkaido University in Japan.

In the study, using rats the team created a xenograft bladder model, and discovered a three to 25-fold increase of the metabolic enzyme aldo-keto reductase 1C1 (AKR1C1).

It was also identified for the first time that AKR1C1 enhances tumour-promoting activities and proved the enzyme blocks the effectiveness of cisplatin and other anti-drugs, which can be inhibited by flufenamic acid, the researchers concluded in the paper published in the journal Scientific Reports.

--IANS

rt/py/vt

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Cheap drug for common cold can stop spread of cancer

A non-steroid, anti-inflammatory drug used for treating common cold has the potential to suppress the spread of bladder cancers as well as reduce their resistance to anti-drugs in mice, Japanese researchers have found.

Bladder -- the seventh most common in males worldwide -- can be grouped into two types: non-muscle-invasive cancer, which have a five-year survival rate of 90 per cent, and muscle-invasive cancer, which have poor prognoses.

The latter are normally treated with such anti-drugs as cisplatin, but tend to become chemo-resistant and, thus, spread to organs such as the lungs and liver, as well as bone, the study said.

The study conducted using animal model showed that injecting flufenamic acid -- a much cheaper cold drug -- into cancerous bladder cells can suppress the cells' invasive activities and restore the effectiveness of anti-drugs.

"The study could pave the way for medical institutions to use flufenamic acid which has unexpectedly been proven to be effective at fighting cancers," said Shinya Tanaka from Hokkaido University in Japan.

In the study, using rats the team created a xenograft bladder model, and discovered a three to 25-fold increase of the metabolic enzyme aldo-keto reductase 1C1 (AKR1C1).

It was also identified for the first time that AKR1C1 enhances tumour-promoting activities and proved the enzyme blocks the effectiveness of cisplatin and other anti-drugs, which can be inhibited by flufenamic acid, the researchers concluded in the paper published in the journal Scientific Reports.

--IANS

rt/py/vt

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard